Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Net Income: 2010-2025

Historic Net Income for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $846,000.

  • Anika Therapeutics' Net Income rose 103.01% to $846,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.8 million, marking a year-over-year decrease of 56.50%. This contributed to the annual value of -$47.6 million for FY2024, which is 39.97% up from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Net Income is $846,000, which was up 24.96% from $677,000 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Net Income high stood at $16.2 million for Q4 2023, and its period low was -$28.1 million during Q3 2024.
  • In the last 3 years, Anika Therapeutics' Net Income had a median value of -$2.6 million in 2024 and averaged -$4.6 million.
  • Examining YoY changes over the last 5 years, Anika Therapeutics' Net Income showed a top increase of 411.38% in 2022 and a maximum decrease of 853.99% in 2022.
  • Over the past 5 years, Anika Therapeutics' Net Income (Quarterly) stood at -$3.2 million in 2021, then surged by 411.38% to $10.1 million in 2022, then skyrocketed by 60.71% to $16.2 million in 2023, then crashed by 219.74% to -$19.4 million in 2024, then surged by 103.01% to $846,000 in 2025.
  • Its Net Income stands at $846,000 for Q3 2025, versus $677,000 for Q2 2025 and -$915,000 for Q1 2025.